retatrutide phase 2 results obesity nejm 2023 🤔 Adults with type diabetes (T2D) and lose less weight on EVERY GLP-1 drug compared to those without diabetes, consistently ~5% less. Now that we have retatrutide's TRIUMPH-2 data today Among participants 4 to 66

Categories such as snacking are seeing particular impact, with chocolate confectionery expenditure declining 18% more among GLP-1 users than among non-user households

Weight Loss and Psychological Transformation Beyond the direct neurochemical effects, the weight loss itself profoundly impacts mental health

A brief word on retatrutide Its a triple agonist hitting GLP-1, GIP, and glucagon receptors and the glucagon component is what sets it apart

Both are GLP-1 receptor agonists initially developed for type 2 diabetes management but have shown significant benefits in weight reduction

GLP-1 drugs can only be prescribed to people after meeting stringent regulatory standards set by agencies like the FDA

Data from cardiovascular outcomes trials suggest that GLP-1 agonists provide cardioprotective effects independent of weight loss, including reduced myocardial infarction rates and improved heart failure outcomes